Prothena | PRTA - Ebitda



金融业
股票价格
USD
资产
USD 349.89M
现金及等价物
USD 329.46M
销售成本
USD 28.94M
流动资产
USD 339.2M
流动负债
USD 32.52M
债务
USD 9.08M
EBIT
USD -27.21M
EBITDA
USD -39.53M
员工
163
EPS每股收益
USD 0.6
股本和储备
USD 312.62M
销售毛利
USD 21K
债务利息支出
USD 349.89M
利息收入
USD 3.35M
贷款资金
USD 0
市值
USD 443.7M
净收入
USD -21.59M
营业费用
USD 27.23M
营业利润
USD -27.21M
普通股股本
USD 53.83M
PE价格收益
22.11
税前利润
USD -21.58M
销售收入
USD 51.08M
销售和管理费用
USD 7.65M
贸易债权人
USD 4.3M
应收帐款人
USD 5.16M


Ebitda 更改 日
Acadia Pharmaceuticals USD 20.31M 15.44M 2025-12
Agios Pharmaceuticals USD -120.31M 4.82M 2025-12
Akebia Therapeutics USD 14.03M 17.19M 2025-03
ALKERMES USD 80.26M 20.05M 2026-03
Alnylam Pharmaceuticals USD 145.22M 236.56M 2025-12
Amgen USD 5.14B 775M 2025-12
Biogen USD 649.7M 76.5M 2026-03
BioMarin Pharmaceutical USD 146.05M 170.22M 2026-03
Exelixis USD 258.29M 15.43M 2026-03
Immunic USD -22.78M 753K 2024-06
Incyte USD 367.97M 46.53M 2026-03
Ionis Pharmaceuticals USD -200.02M 42.89M 2025-12
MacroGenics USD 21.95M 55.39M 2025-09
Nektar Therapeutics USD -31.81M 70K 2023-09
Neurocrine Biosciences USD 193.3M 25.1M 2026-03
Prothena USD -39.53M 12.25M 2025-09
Regeneron Pharmaceuticals USD 1.2B 718.4M 2025-12
Ultragenyx Pharmaceutical USD -99.43M 57.35M 2025-12
Vertex Pharmaceuticals USD 1.19B 195.3M 2026-03
Xoma USD 2.52M 7.98M 2024-06